目的 探究清肝利胆口服液联合腺苷蛋氨酸治疗新生儿肝内胆汁淤积症的效果。方法 选取2015年9月—2018年9月郑州市妇幼保健院收治的肝内胆汁淤积新生儿98例作为研究对象，采用随机数字表法将患儿分为对照组和观察组，每组各49例。对照组静脉滴注注射用丁二磺酸腺苷蛋氨酸，30～60 mg/（kg·d）。观察组在对照组的基础上给予清肝利胆口服液，3～5 mL/次，3次/d。两组均连续治疗15 d。比较两组患者的临床疗效，同时比较两组患者的肝功能相关指标和不良反应发生情况。结果 治疗后，观察组总有效率为95.92%，显著高于对照组的81.63%（P<0.05）。治疗后，两组谷丙转氨酶（ALT）、总胆红素（TBIL）和直接胆红素（DBIL）水平均显著下降（P<0.05）；治疗后，观察组肝功能指标水平显著低于对照组（P<0.05）。两组患儿不良反应发生率比较差异无统计学意义。结论 清肝利胆口服液联合腺苷蛋氨酸可显著改善肝内胆汁淤积症患儿的肝功能，提高治疗效果，且不增加不良反应发生率，值得临床借鉴。

Objective To explore the effect of Qinggan Lidan Oral Liquid combined with ademetionine in treatment of neonatal intrahepatic cholestasis. Methods A total of 98 children with neonatal intrahepatic cholestasis in Women & Infants Hospital of Zhengzhou from September 2015 to September 2018 were selected as the research objects, and the children were divided into control group and observation group by random number table method, with 49 cases in each group. Children in the control group were iv administered with Ademetionine 1,4-Butanedisulfonate for Injection for 30-60 mg/(kg·d). Children in the observation group was given Qinggan Lidan Oral Liquid on the basis of the control group, 3-5mL/time, and three times daily. Both groups received continuous treatment for 15 days. The clinical efficacy of two groups was compared, and the indicators related to liver function and the occurrence of adverse reactions were also compared between two groups. Results After treatment, the total effective rate of the observation group was 95.92%, significantly higher than 81.63% of the control group (P<0.05). After treatment, ALT, TBIL and DBIL levels were decreased significantly (P<0.05). After treatment, the liver function index level of the observation group was significantly lower than that of the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups. Conclusion Qinggan Lidan Oral Liquid combined with ademetionine can significantly improve the liver function of children with intrahepatic cholestasis, improve the treatment effect, and do not increase the incidence of adverse reactions, which is worthy of clinical reference.

R975